Justesen US - Search Results

1

[Lactic acidosis type B. A life-threatening adverse effect of antiretroviral therapy].

Justesen US, Pedersen C. Justesen US, et al. Ugeskr Laeger. 2000 Aug 28;162(35):4664-5. Ugeskr Laeger. 2000. PMID: 10986895 Danish.

2

[Experiences with antiretroviral combination therapy].

Justesen US, Mygind LH, Pedersen SS, Pedersen C. Justesen US, et al. Ugeskr Laeger. 1999 Mar 22;161(12):1747-51. Ugeskr Laeger. 1999. PMID: 10210973 Clinical Trial. Danish.

3

[HIV protease inhibitors and interactions].

Justesen US, Brøsen K, Pedersen C. Justesen US, et al. Ugeskr Laeger. 2000 Aug 28;162(35):4677-81. Ugeskr Laeger. 2000. PMID: 10986900 Review. Danish.

4

Diurnal variation of plasma protease inhibitor concentrations.

Justesen US, Pedersen C. Justesen US, et al. AIDS. 2002 Dec 6;16(18):2487-9. doi: 10.1097/00002030-200212060-00019. AIDS. 2002. PMID: 12461428 Clinical Trial. No abstract available.

5

Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography.

Justesen US, Pedersen C, Klitgaard NA. Justesen US, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 15;783(2):491-500. doi: 10.1016/s1570-0232(02)00728-6. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 12482492

6

Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.

Justesen US, Levring AM, Thomsen A, Lindberg JA, Pedersen C, Tauris P. Justesen US, et al. HIV Med. 2003 Jul;4(3):250-4. doi: 10.1046/j.1468-1293.2003.00153.x. HIV Med. 2003. PMID: 12859324 Free article.

7

Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.

Justesen US, Andersen AB, Klitgaard NA, Brøsen K, Gerstoft J, Pedersen C. Justesen US, et al. Clin Infect Dis. 2004 Feb 1;38(3):426-9. doi: 10.1086/380794. Epub 2004 Jan 12. Clin Infect Dis. 2004. PMID: 14727216 Clinical Trial.

8

The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.

Justesen US, Hansen IM, Andersen AB, Klitgaard NA, Black FT, Gerstoft J, Mathiesen LR, Pedersen C. Justesen US, et al. HIV Med. 2005 Sep;6(5):334-40. doi: 10.1111/j.1468-1293.2005.00317.x. HIV Med. 2005. PMID: 16156881 Free article. Clinical Trial.

9

Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.

Justesen US, Klitgaard NA, Brosen K, Pedersen C. Justesen US, et al. Br J Clin Pharmacol. 2003 Jan;55(1):100-6. doi: 10.1046/j.1365-2125.2003.01734.x. Br J Clin Pharmacol. 2003. PMID: 12534646 Free PMC article. Clinical Trial.

10

Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.

Justesen US, Fox Z, Pedersen C, Cahn P, Gerstoft J, Clumeck N, Losso M, Peters B, Obel N, Castagna A, Dragsted UB, Lundgren JD; MaxCmin1 and 2 trial groups. Justesen US, et al. Basic Clin Pharmacol Toxicol. 2007 Nov;101(5):339-44. doi: 10.1111/j.1742-7843.2007.00117.x. Basic Clin Pharmacol Toxicol. 2007. PMID: 17910618 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters